Accueil > BIGG > Résultat de la recherche

    Résultats: 4

    Guidelines for treatment of drug-susceptible tuberculosis and patient care: 2017 update

    World Health Organization.
    The present guideline update aims to use the best available evidence on the treatment of drug-susceptible TB, as well as on interventions to ensure adequate patient care and support, in order to inform policy decisions made in these technical areas by national TB control programme managers, national poli...
    Tuberculose/traitement médicamenteux, Tuberculose multirésistante/traitement médicamenteux, Antituberculeux/administration et posologie, Protocoles cliniques, Résultat thérapeutique, Fluoroquinolones/administration et posologie, Rifampicine/administration et posologie, Isoniazide/administration et posologie, Pyrazinamide/administration et posologie, Éthambutol/administration et posologie
    Texte intégral

    Guidelines on the Management of Latent Tuberculosis Infection

    World Health Organization.
    The overall objective of the guidelines is to provide public health approach guidance on evidencebased practices for testing, treating and managing LTBI in individuals with the highest risk of progression to active disease. The guidelines are expected to provide the basis and rationale for the developmen...
    Antituberculeux/administration et posologie, Tuberculose latente/traitement médicamenteux, Tuberculose latente/prévention et contrôle, Populations vulnérables, Résultat thérapeutique, Adhésion au traitement médicamenteux, Rifampicine/administration et posologie, Isoniazide/administration et posologie, Association de médicaments, Tuberculose latente/diagnostic
    Texte intégral (lien principal)     Texte intégral (lien alternatif)     Texte intégral (lien alternatif)    

    Recommendation on 36 months isoniazid preventive therapy to adults and adolescents living with HIV in resource-constrained and high TB and HIV-prevalence settings: 2015 update

    World Health Organization.
    In 2011 WHO conditionally recommended the use of at least 36 months of isoniazid preventive therapy (IPT) (as a proxy for lifelong or continuous treatment) for people living with HIV in high TB-prevalence and transmission settings. The evidence of the benefits and harms of 36-month IPT compared to 6-mont...
    Tuberculose/traitement médicamenteux, Infections opportunistes liées au SIDA/traitement médicamenteux, Isoniazide/administration et posologie, Antituberculeux/administration et posologie, Pays en voie de développement
    Texte intégral (lien principal)     Texte intégral (lien alternatif)    

    Rapid advice: treatment of tuberculosis in children

    World Health Organization.
    The World Health Organization (WHO) first published guidance for national tuberculosis control programmes on managing tuberculosis in children (hereafter called “the Guidance”) in 2006. The Guidance follows the principles of a public health approach aimed at optimizing outcomes, including the quality...
    Tuberculose/traitement médicamenteux, Antibiotiques antituberculeux/usage thérapeutique, Isoniazide/administration et posologie, Rifampicine/administration et posologie, Pyrazinamide/administration et posologie, Éthambutol/administration et posologie, Infections à VIH/complications
    Texte intégral